Abstract
Background: We compared insulin resistance and glucose metabolism during growth hormone (GH) therapy between 43 short children born small‐for‐gestational age (SGA) and 42 children identify as growth hormone deficiency (GHD).Methods: The study compared fasting plasma glucose (FPG), fasting immunoreactive insulin (IRI) and homeostasis model assessment insulin resistance index (HOMA‐IR) during 24‐month GH therapy between the two groups.Results: Mean FPG, fasting IRI, and HOMA‐IR values at 3‐month GH therapy were significantly higher than those before and at 12‐ and 24‐month GH therapy in both groups. These markers were significantly higher in short children born SGA than GHD children until 12‐month GH therapy but were not different at 24‐month GH therapy in both groups.Conclusions: The increased secretion of insulin observed in short children born SGA might be a compensatory mechanism for the prevention of hyperglycemia that can progress to diabetes mellitus. However, these metabolic markers gradually declined after 3 months of GH therapy and returned to baseline values at 24 months. These results suggest that short children born SGA have greater insulin resistance than GHD children at the early period of GH therapy, however, increased insulin resistance is improved over a long period.

This publication has 29 references indexed in Scilit: